Cargando…
Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies
CD22-targeted recombinant immunotoxins (rIT) are active in hairy cell leukemia or acute lymphoblastic leukemia (ALL), but not in mantle cell lymphoma (MCL) patients. The goal was to enhance rIT efficacy in vivo and to define a strong combination treatment. Activity of Moxetumomab pasudotox (Moxe) an...
Autores principales: | Müller, Fabian, Stookey, Stephanie, Cunningham, Tyler, Pastan, Ira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458156/ https://www.ncbi.nlm.nih.gov/pubmed/28423727 http://dx.doi.org/10.18632/oncotarget.16141 |
Ejemplares similares
-
Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
por: Mazor, Ronit, et al.
Publicado: (2016) -
Synergistic immunotoxin-paclitaxel combination against lymphoma
por: Müller, Fabian
Publicado: (2017) -
Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012) -
Immunotoxins: From Design to Clinical Application
por: Kreitman, Robert J., et al.
Publicado: (2021) -
Development of Recombinant Immunotoxins for Hairy Cell Leukemia
por: Kreitman, Robert J., et al.
Publicado: (2020)